All hepatitis C virus genotypes respond to therapy
Recipients of hepatitis C-infected kidneys treated with direct-acting antiviral agents are disease-free one year post-transplant.
More patients could take advantage of shorter direct-acting antiviral treatment duration.
Females, Hispanics screened less often for highly curable infection.
More effort needed to integrate screening with follow-up care to prevent spread of the virus.
With the advent of new direct-acting antiviral agents, HCV treatment has greatly improved, making identification of infected individuals even more imperative.
Those using illicit drugs and co-infected with HIV and hepatitis C are willing to use direct-acting anti-viral agents, says a new study.
Hispanic and Asian patients have a higher risk of cirrhosis and liver cancer, but direct-antiviral treatment eliminates ethnic disparities.
Researchers: Treatment-naïve patients infected with genotype 1 hepatitis C virus can receive shorter regimen.
Targeted efforts may improve the reach of treatment with direct-acting antiviral agents, according to a new study.